Objective: Macrophage migration inhibitory factor (MIF) is a key regulator of both atherosclerosis and systemic lupus erythematosus (SLE), yet factors leading to its overproduction remain unclear. To explore regulation of MIF in SLE, we studied effects and potential mechanisms of type I interferon (IFN) and artesunate (ART), an antimalarial agent extracted from Chinese herbs, on levels of MIF. Methods: Serum and peripheral blood cells from SLE patients and healthy controls were measured for MIF levels by ELISA and type I IFNinducible gene expressions by real-time PCR, respectively, and assessed for associations by Spearman correlation. ART was added to human umbilical vein endothelial cell (HUVEC) cultures with or without prior IFNa-1b stimulation and to SLE peripheral blood mononuclear cell (PBMC) cultures. Protein levels of STATs and phosphorylated (p-) STATs in HUVECs were determined by Western blotting. Results: Serum MIF levels were elevated in SLE patients and positively associated with disease activity (r ¼ 0.86, p < 0.0001), accumulated damage (r ¼ 0.34, p < 0.05), and IFN scores in SLE PBMCs (r ¼ 0.74, p ¼ 0.0002). The addition of IFNa-1b promoted MIF production in a time-and dose-dependent manner in HUVEC cultures. ART could inhibit expressions of IFN-inducible genes (LY6E and ISG15) in both HUVEC and SLE PBMC cultures, and suppress MIF production and overexpression of p-STAT1, but not p-STAT3 or STAT5, induced by IFNa-1b stimulation. IFNginduced expression of p-STAT1 in HUVECs was not inhibited by ART. Conclusion: MIF could be regulated by type I IFN in SLE patients. ART counteracts the effect of IFNa to inhibit MIF production by blocking STAT1 phosphorylation and thus may have therapeutic potential for SLE-associated atherosclerosis. Lupus (2017) 26, 62-72.
Introduction
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease characterized by the production of autoantibodies and end organ damage from immune complex deposition. 1 In 1976, Urowitz et al. noted premature myocardial infarction among patients with SLE. 2 Since this pioneering discovery, many follow-up studies have demonstrated that the incidence of coronary artery disease in women with SLE is much higher than in an age-matched general population, which could not be fully accounted for by traditional risk factors. 3 Patients with SLE-associated atherosclerosis have an earlier occurrence, a longer duration of lupus and a higher damage-index score. 4, 5 However, the molecular mechanisms of accelerated atherosclerosis in SLE remain to be elucidated.
Macrophage migration inhibitory factor (MIF) is released upon pro-inflammatory activation and exerts an upstream role in regulating the innate immune response. High-expression MIF alleles are associated with disease risk in SLE, 6 while anti-MIF treatment reduces functional and histological indices of glomerulonephritis in different strains of lupus-prone mice, 7 indicating that MIF is a key regulator for developing disease manifestations. Of note, a growing body of literature has suggested that MIF also plays an important role in the pathogenesis of atherosclerosis. MIF expression within atheromatous plaques is closely associated with progression and instability in human disease, and inhibition of MIF activity prevents atherosclerosis in animal models. 8, 9 Thus, MIF may be a common mediator for accelerated atherosclerosis in SLE.
At present, it is unclear how MIF is modulated in SLE patients and there is a lack of preventive strategies targeting this process. Over the past decade, interferon-alpha (IFNa) or type I IFN has been identified to play a central role in the pathogenesis of SLE, 10, 11 and an association between type I IFN, vascular damage and progression of atherosclerosis has emerged. 12 Artesunate (ART) is a semi-synthetic derivative of a Chinese herb named artemisinin that is commonly used as an antimalarial agent in treating Chinese patients. Previously we have demonstrated that ART could inhibit the progression of lupus disease and reverse the pathologic lesion of nephritis in the MRL/lpr mouse model. 13 Since ART could also exert an anti-angiogenic effect by decreasing the levels of vasoactive factors and inducing endothelial cell apoptosis, it is hypothesized that this drug may work on the regulation of atherosclerosis. 14 In the current study, we showed for the first time that MIF level was associated with type I IFN gene expression signature in SLE patients. ART treatment downregulated IFNa-induced MIF production through the inhibition of phosphorylation of signal transducer and activator of transcription 1 (STAT1), and herein may have a potential role in ameliorating SLE-associated atherosclerosis.
Materials and methods

Patients and controls
The demographics of SLE patients and normal controls are shown in Table 1 . Thirty-five SLE inpatients (35.2 AE 12.8 years old, including 34 female and one male) were enrolled in the study and all of them fulElled the classification criteria of SLE proposed by the American College of Rheumatology (ACR). 15 SLE disease activity was assessed by the Systemic Lupus Erythematosus Disease Activity Index, 16 and damage was measured by Systemic Lupus International Collaborating Clinics/ ACR Damage Index (SLICC) scores. 17 The average dose of corticosteroids was 32.6 AE 24.0 mg/day (counted as the equivalent dose to methylprednisolone) at the time of blood draw. Twenty-one healthy donors (34.5 AE 8.5 years old, 19 female and two male) were recruited as normal controls. The study was approved by the Ethics Committee at The Affiliated Drum Tower Hospital of Nanjing University Medical School. Informed consent was obtained from each patient and healthy donor.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were purchased from Shanghai Fumeng Gene Biologicals (Shanghai, China). Cells were resuspended at 3 Â 10 5 per well (1.5 Â 10 5 /ml) in Dulbecco's Modified Eagle Medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco) with or without the presence of different concentrations of IFNa-1b (200 U/ml, 1000 U/ml, 2000 U/ml) and incubated at 37 C with 5% CO 2 for six, 12 or 24 hours. Then the culture medium was replaced with a medium containing ART at the concentration of 5 or 20 mmol/l, with dexamethasone sodium phosphate (100 ng/ml, 0.19 mM) or fludarabine (50 mM) applied as a positive control. Twelve and 24 hours later, cells and supernatants were harvested for further measurements. To confirm the results from HUVECs, peripheral blood mononuclear cells (PBMCs) from SLE patients were cultured with ART (5 or 20 mM) or dexamethasone sodium phosphate (100 ng/ml) at 3 Â 10 5 per well for 24 hours. Gene expression measuring A 2 to 3 ml blood sample or 1 Â 10 5 HUVECs was collected, and total RNA was extracted immediately using Trizol reagent (Invitrogen, USA). RNA was reverse-transcribed and quantified by real-time polymerase chain reaction (Q-PCR) using the PrimeScript RT-PCR and SYBR Õ Premix Ex Taq TM kit (TaKaRa Biotechnology) for the detection of type I IFN-inducible gene (MX1, OASL, OAS1, ISG15 and LY6E) expression in triplicates in the ABI 7500 FAST real-time PCR detection system (Applied Biosystems, USA). All primers were purchased from TaKaRa (Dalian, China) and the sequences were the same as previously described. 18 Human ribosomal protein, large, P0 (RPLP0) was used as the house-keeping gene to normalize cellular RNA amounts. After the realtime PCR procedure, mean cycle threshold (CT) value of a target gene was obtained for each sample. Relative gene expression values were presented as 2 ÀÁÁCT , and IFN scores were calculated using MX1, OASL, OAS1, ISG15 and LY6E messenger RNA (mRNA) expression as previously described. 19 Because these five genes exhibited highly correlated expressions among each other, 19 in vitro studies two of them (LY6E and ISG15) were measured to represent the status of IFN-inducible gene expressions.
Protein analysis
HUVECs were harvested and resuspended in lysis buffer for 30 minutes, and then centrifuged at 14,000 g for 10 minutes at 4 C. After centrifugation, cell lysates were subjected to 10% sodium dodecylsulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Millipore, USA). After blocking with 5% skim milk, the membranes were incubated with primary antibodies at 4 C overnight, including antibodies against phosphorylated (p-) STAT1, STAT1, p-STAT3, STAT3, p-STAT5, STAT5 and GAPDH (Cell Signaling Technology). After washing with Tris-buffered saline with Tween 20, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody (1:5000-1:10000) for 30 minutes and the bands were visualized in a luminol-based detection system with enhanced chemiluminescence (Millipore, USA). Anti-GAPDH antibody (Cell Signaling Technology) was used as a loading control. MIF levels in serum or cultured supernatants were determined by enzyme-linked immunosorbent assay (ELISA) (R&D, USA) with samples diluted in 1:10 or 1:20.
Statistical analysis
All data were analyzed using Prism version 6.0 software (GraphPad, San Diego, CA, USA). Comparisons between two groups were made by unpaired t test or Mann-Whitney tests when the data were not normally distributed, and results were correspondingly shown as mean AE SD or median (interquartile range, IQRs). Spearman correlation was used to depict relationships between two factors. To determine whether the parameters were significantly altered after the treatment of ART in vitro, one-way analysis of variance (ANOVA) was applied, followed by Dunnett's multiple comparisons test. A p < 0.05 was considered to be statistically significant.
Results
Increased serum MIF levels in SLE patients
Compared to healthy controls, serum MIF levels were significantly elevated in SLE patients (18.7 (IQRs 12.5, 29.9) ng/ml vs. 1.8 (1.0, 2.0) ng/ml, p < 0.0001) (Figure 1(a) ). Positive correlations were detected between MIF levels and SLEDAI scores (r ¼ 0.86, p < 0.0001), SLICC scores (r ¼ 0.34, p ¼ 0.048), as well as the dose of methylprednisolone at the time of blood draw (r ¼ 0.45, p ¼ 0.016) ( Figure 1(b) , (c), and (d), respectively), implying that MIF is an important contributor to both disease activity and accumulated damage in SLE, which is reflected in the treatment dosage of steroids.
The disturbance of MIF was related to aberrant IFN-inducible gene expression in SLE patients
To explore potential factors that participated in upregulation of MIF in SLE, expressions of five type I IFN-inducible genes (MX1, OASL, OAS1, ISG15 and LY6E) in PBMCs from SLE patients and healthy controls were measured. Q-PCR analysis demonstrated that significantly higher expressions of all five IFN inducible genes were present in patients with SLE (p all < 0.001, except for OAS1, where p < 0.05) (Figure 2 (a)-(e)). As shown in Figure 2 (f), IFN scores that were calculated according to the expression levels of the five IFN inducible genes were positively correlated to SLEDAI scores (r ¼ 0.69, p ¼ 0.0007). The increase of IFN scores was robustly associated with the elevation of MIF levels (r ¼ 0.74, p ¼ 0.0002) (Figure 2(g) ), supporting a link between circulating MIF levels of SLE patients and elevated levels Production of macrophage migration inhibitory factor in patients with SLE X Feng et al.
of type I IFN-inducible gene expression in SLE PBMCs.
IFN could directly modulate MIF levels in vitro
To investigate whether type I IFN did have an effect on MIF regulation, a human endothelial cell line, HUVECs, was cultured with or without the addition of IFNa-1b. As expected, HUVECs expressed higher mRNA levels of type I IFN-inducible genes (as represented by LY6E and ISG15) after IFNa stimulation (p < 0.05) (see the control group in Figure 3 ). MIF levels were significantly elevated at 24 hours (31.8 AE 4.5 ng/ml vs. 22.4 AE 1.8 ng/ml, p < 0.01) but not at six hours or 12 hours after IFNa treatment (Figure 4(a) ). After stimulated by different concentrations of IFNa for 24 hours, MIF levels were increased in all three groups compared with that in the control group and the effect was most significantly different at the highest dose in the 2000 U/ml group (60.6 AE 11.0 ng/ml vs. 22.4 AE 1.8 ng/ml, p < 0.001) (Figure 4(b) ), indicating that type I IFN is capable of promoting MIF production in a time-and dosedependent manner.
ART downregulated type I IFN-inducible gene expression and MIF production
To explore the role of ART on type I IFN and MIF, HUVECs were exposed to IFNa-1b and then treated by ART (5 and 20 mM) or dexamethasone (as a positive control). As shown in Figure 3 , there was a dramatic decline of IFN-inducible gene (LY6E and ISG15) expression after ART and dexamethasone treatment, either with or without prior stimulation of IFNa (1000 U/ml), indicating that ART could inhibit the activation of the IFN pathway. After culturing with ART for 24 hours, a significant decline of MIF levels was observed (24.5 AE 0.5 ng/ml in the ART 5 mM group, 24.4 AE 0.3 ng/ml in the ART 20 mM group, all p < 0.001 compared to 29.4 AE 0.6 ng/ml in the IFNa control group) ( Figure 4(d) ), suggesting that ART could counteract IFNa-triggered MIF production.
To further confirm the effect of ART, we assessed MIF production in SLE PBMC cultures in the presence or absence of ART at a dose of 20 mM. Similar to that in HUVECs, ART significantly decreased the mRNA expressions of LY6E and ISG15 (both p < 0.01) ( Figure 5(a) , (b)) and downregulated MIF levels (13.5 AE 3.5 ng/ml vs. 50.9 AE 6.5 ng/ml, p < 0.001) ( Figure 5(c) ). Thus, ART could act not only on endothelial cells, but also on PBMCs to inhibit MIF production.
ART inhibited MIF production through the blockade of STAT1 phosphorylation
Given that the biological activities of IFNs are triggered by the STAT signaling cascade, 21 we studied the activation of STATs after ART treatment. Western blotting demonstrated that IFNa-1b promoted tyrosine phosphorylation of STAT1 but not STAT3 or STAT5 in cultured HUVECs (Figure 6(a) ). When treated by ART at a dose of 20 mM for 24 hours, IFNa-1b induced elevation of p-STAT1 was greatly downregulated (Figure 6(b) ).
Consistently, MIF levels in cultured supernatants were also increased after IFNa-1b stimulation, while ART had a similar effect as that of fludarabine, a specific STAT1 inhibitor, in attenuating IFNa-induced MIF production ( Figure 6(c) ). To rule out the effect of type II IFN, HUVECs were stimulated with 10 ng/ml IFNg for 24 hours and cultured with ART for another 24 hours. As shown in Figure 6(d) , ART treatment did not reverse IFNg-induced STAT1 phosphorylation.
Discussion
Individuals with SLE have a striking increase in the incidence of premature atherosclerosis compared to their sex-and age-matched controls, which has been recognized as one of the leading cause of morbidity and mortality for this prototypical autoimmune disease. 22 Recently, activation of the type I IFN system has been shown to contribute, at least partially, to accelerated atherosclerosis in SLE patients, 23 yet the mechanisms remain to be elucidated. In this study, we confirmed that MIF, a chemokine-like inflammatory regulator related to either atherosclerosis or lupus, was highly expressed in SLE patients, especially those with active diseases. Our data demonstrated for the first time that elevated type I IFN could lead to the abnormal production of MIF, while ART, an antimalarial agent extracted from Chinese herbs, counteracted the effect of type I IFN by blocking STAT1 phosphorylation. Based on these data, we propose that ART may serve as a novel and feasible therapy both for SLE and SLE-associated arthrosclerosis.
Our data also demonstrated that MIF was highly expressed in SLE patients and associated with both disease activity and accumulated organ damage. MIF, first described as a T-cell cytokine important for inhibiting macrophage migration, is now known to be secreted by both immune and nonimmune cell types through the autocrine or paracrine modes of action and to have diverse immunologic functions. 24 There is an impressive body of evidence supporting a key role for MIF in the pathogenesis of SLE, as the circulating level and the tissue expression of MIF are elevated in SLE patients, and the MIF high-expression alleles are associated with increased prevalence of SLE. 6, 25 In addition, lupus-prone mice deEcient in MIF have been reported to exhibit prolonged survival and marked reductions in renal and skin lesions despite no effects on T and B cells, while targeting the MIF-MIF receptor interaction by small-molecule antagonism downregulates MIF-dependent Production of macrophage migration inhibitory factor in patients with SLE X Feng et al.
pathways of tissue damage. 7, 26 MIF may directly accelerate atherosclerosis, since it is highly expressed in different stages of human atherosclerosis, 27 and MIF inhibition induces the stabilization and even regression of atherosclerotic plaques in different experimental models. 8, 28, 29 Thus, the elevation of MIF in SLE patients could not only exacerbate lupus diseases but also promote atherosclerosis. Our next question is why MIF levels fluctuated in SLE. In the past decade, IFNa has been proposed to play an important role in SLE etiology and pathogenesis. There are many studies including ours demonstrating that IFNa levels or type I IFN-inducible gene expressions increase during SLE flares and multiple organ involvement. 20, 30 Recently, a link between type I IFN and premature atherosclerosis in SLE has been established by the data showing that IFNa priming promotes lipid uptake and macrophage-derived foam cell formation. 12 In this study, we showed for the first time that MIF levels were related to increased IFN-inducible gene expression in SLE patients. In vitro treatment of IFNa confirmed the relationship between type I IFN and MIF, implying that over-expressed type I IFN may promote atherosclerosis in SLE through the modulation of MIF. Currently, the available therapy for atherosclerosis primarily targets hyperlipidemia and prevention of thrombosis, even though it has long been identified as having inflammatory components contributing to its pathogenesis. Unfortunately, routine statin use over three years has no significant effect on subclinical atherosclerosis progression in young SLE patients. 31 With the exception of mycophenolate mofetil and hydroxychloroquine, 32, 33 the availability of beneficial treatments to treat SLE-associated atherosclerosis is greatly limited. Since MIF plays an important role in the progression of atherosclerosis, the design of new inhibitors targeting MIF and the study of their effects on the biologic functions of this factor will be extremely valuable and promising for treatment of lupus atherosclerosis. 24 Artemisinins are a family of sesquiterpene trioxane lactone antimalarial agents originally derived from Artemisia annua L., among which ART is the most studied analog. With its established safety record in millions of malarial patients, recently ART has also been investigated in other diseases such as virus or fungal infections, cancers and autoimmune diseases. 34 Consistent with our previous findings, 13 this kind of drug significantly ameliorates lupus-like disease in experimental murine models of SLE, with comparable or even superior efficacy to that of glucocorticoids or immunosuppressants. 35, 36 The anti-inFammatory effects of ART could be attributed to the inhibition of various cytokines and diverse signaling pathways. 37, 38 Here we showed that ART directly inhibited the expression of IFN-inducible genes and counteracted the effect of IFNa on MIF production, suggesting that ART acts through the modulation of the type I IFN pathway. Upon IFN-induced activation, the STAT proteins are phosphorylated and translocated into the nucleus to bind specific elements within the promoters of IFN-stimulated genes. 21 Treatment with an artemisinin analog has been found to significantly suppress the phosphorylation of STAT-1, STAT-3, and STAT-5 but not STAT-4 and STAT-6. 36 However, only the phosphorylation of STAT-1 was found to be downregulated by ART in this study, which was compatible to that of fludarabine, a selective STAT1 inhibitor. In summary, here we showed that the production of MIF was upregulated by type I IFN in vitro. The IFNa-MIF axis could represent a new pathway for the development of arthrosclerosis in SLE. ART acted through the inhibition of STAT1 phosphorylation to counteract the effect of type I IFN, leading to the decline of MIF level, therefore may be helpful to relieve both lupus and atherosclerosis in SLE patients.
